Gilman Hill Asset Management LLC Purchases Shares of 2,250 SPDR S&P Biotech ETF (NYSEARCA:XBI)

Gilman Hill Asset Management LLC acquired a new position in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI) in the 4th quarter, HoldingsChannel reports. The institutional investor acquired 2,250 shares of the exchange traded fund’s stock, valued at approximately $203,000.

A number of other hedge funds have also modified their holdings of the stock. Mission Hills Financial Advisory LLC boosted its position in shares of SPDR S&P Biotech ETF by 14.3% in the 4th quarter. Mission Hills Financial Advisory LLC now owns 36,111 shares of the exchange traded fund’s stock valued at $3,252,000 after purchasing an additional 4,531 shares during the period. Herbst Group LLC boosted its holdings in shares of SPDR S&P Biotech ETF by 19.9% in the fourth quarter. Herbst Group LLC now owns 4,830 shares of the exchange traded fund’s stock worth $435,000 after buying an additional 800 shares during the period. Ameritas Advisory Services LLC increased its position in shares of SPDR S&P Biotech ETF by 11.9% in the fourth quarter. Ameritas Advisory Services LLC now owns 10,684 shares of the exchange traded fund’s stock worth $962,000 after acquiring an additional 1,137 shares in the last quarter. Shelton Wealth Management LLC lifted its position in shares of SPDR S&P Biotech ETF by 6.7% in the 4th quarter. Shelton Wealth Management LLC now owns 4,359 shares of the exchange traded fund’s stock valued at $393,000 after acquiring an additional 273 shares in the last quarter. Finally, Carnegie Investment Counsel boosted its stake in SPDR S&P Biotech ETF by 6.0% in the 4th quarter. Carnegie Investment Counsel now owns 101,106 shares of the exchange traded fund’s stock worth $9,106,000 after purchasing an additional 5,683 shares during the period.

SPDR S&P Biotech ETF Stock Performance

NYSEARCA XBI opened at $87.97 on Tuesday. The firm’s 50 day moving average price is $93.78 and its two-hundred day moving average price is $96.96. The stock has a market cap of $6.71 billion, a price-to-earnings ratio of 11.47 and a beta of 1.11. SPDR S&P Biotech ETF has a twelve month low of $81.14 and a twelve month high of $105.47.

About SPDR S&P Biotech ETF

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.